Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
457.35
+0.32 (0.07%)
Oct 16, 2026, 3:25 PM EST
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
$754,676
Profits / Employee
$147,929
Market Cap
367.67B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Veradigm | 2,300 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 105 |
| Silence Therapeutics | 88 |
| Elite Pharmaceuticals | 65 |
| Vaxart | 65 |
| CytoDyn | 14 |
Roche Holding AG News
- 17 hours ago - FDA Approves Roche's Enspryng For Thyroid Eye Disease - Nasdaq
- 19 hours ago - Roche Announces FDA Approval Of Enspryng - Nasdaq
- 19 hours ago - FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) - Business Wire
- 19 hours ago - FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) - GlobeNewsWire
- 2 days ago - Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy - Reuters
- 3 days ago - Rona Therapeutics Licenses Obesity Drug Candidate To Roche In Deal Worth Up To $1.16 Billion - Nasdaq
- 3 days ago - Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics - Reuters
- 3 days ago - Nurix Swings To Profit In Q3 As Roche Deal Drives Revenue Surge - Nasdaq